0001567619-22-000817.txt : 20220106 0001567619-22-000817.hdr.sgml : 20220106 20220106185529 ACCESSION NUMBER: 0001567619-22-000817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220104 FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Saxonov Serge CENTRAL INDEX KEY: 0001786720 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 22516102 MAIL ADDRESS: STREET 1: 10X GENOMICS, INC. STREET 2: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc1.xml FORM 4 X0306 4 2022-01-04 0 0001770787 10x Genomics, Inc. TXG 0001786720 Saxonov Serge C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 1 1 0 0 Chief Executive Officer Class A Common Stock 2022-01-04 4 M 0 3037 11.48 A 937255 D Class A Common Stock 2022-01-04 4 S 0 1000 138.8636 D 936255 D Class A Common Stock 2022-01-04 4 S 0 3100 139.8207 D 933155 D Class A Common Stock 2022-01-04 4 S 0 5368 140.9580 D 927787 D Class A Common Stock 2022-01-04 4 S 0 2932 141.7179 D 924855 D Class A Common Stock 2022-01-04 4 S 0 700 143.1125 D 924155 D Class A Common Stock 2022-01-04 4 S 0 1400 144.7818 D 922755 D Class A Common Stock 2022-01-04 4 S 0 500 145.3260 D 922255 D Class A Common Stock 4138 I See footnote Class A Common Stock 89960 I See footnote Stock Option (right to buy) 11.48 2022-01-04 4 M 0 3037 0.00 D 2029-05-10 Class A Common Stock 3037 45559 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $138.29 to $139.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $139.33 to $140.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $140.38 to $141.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $141.38 to $142.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $142.99 to $143.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $144.185 to $145.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $145.19 to $145.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. This option, originally for 145,786 shares, of which 100,227 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2022-01-06